EP2476701A1 - Antimikrobielle mittel auf basis von hemin-derivaten - Google Patents

Antimikrobielle mittel auf basis von hemin-derivaten Download PDF

Info

Publication number
EP2476701A1
EP2476701A1 EP10815682A EP10815682A EP2476701A1 EP 2476701 A1 EP2476701 A1 EP 2476701A1 EP 10815682 A EP10815682 A EP 10815682A EP 10815682 A EP10815682 A EP 10815682A EP 2476701 A1 EP2476701 A1 EP 2476701A1
Authority
EP
European Patent Office
Prior art keywords
trp
leu
val
arg
nhch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10815682A
Other languages
English (en)
French (fr)
Other versions
EP2476701B1 (de
EP2476701A4 (de
EP2476701B8 (de
Inventor
Vladimir Evgenievich Nebolsin
Galina Alexandrovna Zheltukhina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obschestvo S Ogranichennoi Otvetstvennostiyu "phar
Original Assignee
Pharmenterprises OOO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmenterprises OOO filed Critical Pharmenterprises OOO
Priority to PL10815682T priority Critical patent/PL2476701T3/pl
Publication of EP2476701A1 publication Critical patent/EP2476701A1/de
Publication of EP2476701A4 publication Critical patent/EP2476701A4/de
Publication of EP2476701B1 publication Critical patent/EP2476701B1/de
Application granted granted Critical
Publication of EP2476701B8 publication Critical patent/EP2476701B8/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to the field of bioorganic chemistry and is directed to the development of novel antimicrobial agents and compositions of hemin derivatives and to the production of novel hemin derivatives.
  • Bacteria cause epidemic diseases such as cholera, typhoid fever, paratyphoid fever, plague, diphtheria, tularemia, brucellosis, as well as tuberculosis, septicemia (blood poisoning), leprosy, syphilis, and others.
  • bacteria cause equinia, anthrax, tuberculosis, and other diseases.
  • Fungal diseases mainly affect the skin and mucous membranes, particular examples being keratomycoses, microsporum, trichophytosis, and cryptococcosis.
  • antimicrobial agents such as antibacterial agents (including antibiotics) and antifungal agents.
  • antibacterial agents including antibiotics
  • antifungal agents many know agents suffer from drawbacks such as toxicity, sensitivity to proteolytic enzymes, a hemolytic effect, and an insufficient range of antimicrobial activity.
  • bacteria rapidly develop resistance toward known antimicrobial agents, primarily antibiotics.
  • a search for novel nontoxic and biocompatible antimicrobial agents that would not cause resistance is of great interest.
  • Hemin is known to have an antimicrobial activity against Staphylococcus aureus [ Y. Nitzan, H. Ladan, S. Gozansky, and Z. Malik, "Characterization of Hemin Antibacterial Action on Staphylococcus aureus,” FEMS Microbiol. Lett., 1987, Vol. 48 (3), pp. 401-406 ].
  • the use of hemin as an antibacterial agent is hampered by its water insolubility, hemolytic activity, and short-term antibacterial effect.
  • antimicrobial activity of the aforementioned hemin derivatives is, however, not known in the art.
  • Compound II is effective against Gram-positive bacteria [ W. E. Herrell and D. Heilman, "Experimental and Clinical Studies on Gramicidin,” J. Clin. Invest., 1941, Vol. 20, No 583 ] and against some viruses, in particular herpes virus [ US Patent No. 6001808, 1999 ].
  • Compound III is effective primarily against Gram-positive bacteria in concentrations of 5 to 15 ⁇ M [ Jingbo Xiao, Bernard Weisblum, and Peter Wipf, "Electrostatic versus Steric Effects in Peptidomimicry: Synthesis and Secondary Structure Analysis of Gramicidin S Analogues with (E)-Alkene Peptide Isosteres,” J. Am. Chem.
  • Arg-Gly-Asp peptide (IV) which is a fragment of cecropin family antimicrobial peptides, many microbial proteins, and mammal cell surface fibronectin [ A. J. Kastin, "Handbook of Biologically Active Peptides,” Elsevier/Academic Press, USA, 2006, p. 576 ].
  • IV Arg-Gly-Asp peptide
  • the invention relates to an antimicrobial (in particular, antibacterial and/or antifungal) agent based on the aforementioned compounds of formula (I) and the corresponding pharmaceutical, antiseptic, and/or disinfectant compositions, and to a method for treating and/or preventing diseases caused by microorganisms.
  • an antimicrobial (in particular, antibacterial and/or antifungal) agent based on the aforementioned compounds of formula (I) and the corresponding pharmaceutical, antiseptic, and/or disinfectant compositions, and to a method for treating and/or preventing diseases caused by microorganisms.
  • hemin derivatives of formula (I) consist in their biocompatibility and biodegradability, low toxicity with respect to normal human cells, the absence of hemolytic effect, and a high antibacterial efficacy, in particular, against resistant strains, combined with an antifungal activity.
  • the inventors suggest that the antimicrobial effect of the compounds of formula (I) may partially arise from their destructive action on lipid membranes, this action known to be one of the major mechanisms of the antimicrobial effect. This action is demonstrated in Example 12 and Fig. 1 .
  • Antimicrobial activity comprises both antibacterial and antifungal activities.
  • the above-described compounds of formula (I) are active against Gram-positive bacteria, such as Staphylococcus (e.g., Staphylococcus aureus ), Bacillus (e.g., Bacillus subtilis), Enterococcus ( e.g ., Enterococcus faecalis), and Micrococcus (e.g., Micrococcus luteus) bacterial genera, in particular, against bacteria that are resistant to known antibacterial agents.
  • the above-listed bacteria are Bacillus subtilis BKM B-501, Staphylococcus aureus 209P, Enterococcus faecalis BKM B-871, or Micrococcus luteus BKM Ac-2230 strains.
  • the aforementioned compounds have antibacterial activity against Staphylococcus aureus No. 25923 ATCC, Staphylococcus aureus No. 100 KC, Staphylococcus epidermidis No. 533, Enterococcusfaecalis No. 559, or Enterococcusfaecium No. 569 resistant strains.
  • the above-described compounds of formula (I) are active against Cryptococcus microfungi (in particular, Cryptococcus neoformans, preferably the Cryptococcus neoformans No. 3465 strain) and Candida microfungi (in particular, Candida albicans, preferably the Candida albicans No. 927 strain).
  • Cryptococcus microfungi in particular, Cryptococcus neoformans, preferably the Cryptococcus neoformans No. 3465 strain
  • Candida microfungi in particular, Candida albicans, preferably the Candida albicans No. 927 strain.
  • the compounds of formula (I) can exist as isomers or mixtures of isomers, which are fully covered by the scope of the claimed invention. For example, if one of the two carboxy groups of hemin is modified, a mixture of (6) and (7) derivatives can be formed.
  • the compounds of formula (I) can be used either in the form of salts with pharmaceutically acceptable acids (e.g., lactic, tartaric, citric, hydrochloric, or another acid), or in the form of salts of their carboxy groups with alkali or alkaline-earth metal ions (such as sodium, potassium, and calcium) or with, for example, pharmaceutically acceptable bases (such as ammonia and ethanolamine).
  • pharmaceutically acceptable acids e.g., lactic, tartaric, citric, hydrochloric, or another acid
  • alkali or alkaline-earth metal ions such as sodium, potassium, and calcium
  • pharmaceutically acceptable bases such as ammonia and ethanolamine
  • compositions e.g., in solid, semisolid, or liquid forms
  • an organic or inorganic carrier or excipient e.g., a pharmaceutically acceptable carrier or excipient.
  • the active ingredient in the composition can be formulated with conventional nontoxic and pharmaceutically acceptable carriers that are suitable for preparing solutions, tablets, pills, capsules, suppositories, emulsions, suspensions, sprays, inhalers, drops, ointments, or other dosage forms.
  • Carriers can be water, glucose, lactose, gum arabic, gelatin, starch, magnesium trixylitol, talc, cornstarch, urea, polyethylene glycol, and other carriers suitable for manufacturing solid, soft, or liquid preparations.
  • stabilizers, thickeners, coloring agents, and flavoring agents may be used as additives.
  • a compound of formula (I) is contained in the composition in an amount sufficient for providing the antimicrobial effect.
  • the amount of the active ingredient formulated with a carrier can be varied depending on the recipient of therapy and on the particular route of administration of the therapeutic agent.
  • the content of the active principle in the solution ranges from 0.001 to 1% by weight.
  • Diluents for the compounds can be 0.9% sodium chloride solution, distilled water, Novocain solution for injections, Ringer's solution, and glucose solution.
  • the amount of the compound ranges from 1.0 to 100.0 mg per unit dosage form.
  • the pharmaceutical excipient can be any pharmaceutically suitable base.
  • compounds of general formula (I) are both water-soluble and lipophilic, they can be used as aqueous solutions, alcoholic solutions, ointments, creams, etc.
  • the invention relates to an antimicrobial therapeutic agent based on the aforementioned compounds of formula (I) and to a method for treating diseases caused by the aforementioned bacteria and/or microfungi, this method comprising administering to a patient in need thereof said compound of formula (I) or a pharmaceutical composition thereof.
  • the method is intended for treating mammal patients, in particular humans.
  • the recommended doses of a compound of formula (I) are from 0.01 to 10 mg/kg.
  • compounds of formula (I) have antibacterial and antifungal activities, they can likewise be used as (or in) antiseptic and/or disinfectant agents.
  • These agents can be prepared as, for example, solutions with diverse solvents, such as water and lower alcohols (e.g., 1-propanol or 2-propanol).
  • One more aspect of the invention relates to a process for producing the above-described novel compounds of formula (I).
  • Compounds of formula (I) are produced by reacting a hemin derivative activated at carboxy group(s) with an amino component.
  • the amino groups of amino components are acylated with hemin bis-N-oxysuccinimide ester; or, for preparing monohemin derivatives, with hemin 6(7)-mono-N-oxy-5-norbomene-2,3-dicarboximide ester; or with a hemin derivative activated at one carboxy group, wherein the activating agent is di-tert-butyl pyrocarbonate in the presence of pyridine.
  • the reactions are carried out in DMF for 0.5 to 2 h at a temperature of from -15° to +30°C.
  • the reagents used were: L-amino acids and their derivatives purchased from Bachem (Germany) and Reanal (Hungary); DOPC (from Sigma-Aldrich); carboxyfluorescein (Fluka, Germany); MES (Sigma-Aldrich); Tris (Sigma-Aldrich); gramicidin D (Sigma-Aldrich); gramicidin S (Kraspharma, Russia); and analytical reagent grade (the Russian standard) potassium chloride (Khimmed, Russia).
  • IR spectra were recorded on a Magna 750 (Nicolet, USA) Fourier-transform spectrometer.
  • Liposomes were obtained with an Avanti (Avanti Polar Lipids, USA) mini-extruder.
  • Protohemin IX 6(7)-Mono(-Val-Gly-Ala-D-Leu-Ala-D-Val-Val-D-Val-Trp-D-Leu-X-D-Leu-Trp-D-Leu-Trp-NH-CH 2 CH 2 OH)amide (Compound XII, wherein one of R 1 and R 2 is -OH and the other is -Val-Gly-Ala-D-Leu-Ala-D-Val-Val-D-Val-Trp-D-Leu-X-D-Leu-Trp-D-Leu-Trp-NH-CH 2 CH 2 OH, wherein X Trp, Tyr, Phe)
  • the peptidyl polymer was filtered off, washed with dichloroethane (2 min ⁇ 3), DMF (2 min ⁇ 2), isopropanol (2 min ⁇ 2), DMF (2 min ⁇ 2), isopropanol (2 min ⁇ 2), methanol (2 min ⁇ 1), and diethyl ether (2 min ⁇ 2), and vacuum dried by a water jet.
  • the extent of resin substitution was determined spectrophotometrically.
  • the resin was filtered off, a filtrate aliquot was taken out, and the optical absorption of the solution of the product N-(9-fluorenylmethyl)piperidine was measured at 289 nm.
  • the Fmoc-Phe content of the polymer was 0.3 mmol/g.
  • the peptidyl polymer was filtered off and washed with dichloroethane (2 min ⁇ 3), DMF (2 min ⁇ 2), isopropanol (2 min ⁇ 2), DMF (2 min ⁇ 2), isopropanol (2 min ⁇ 2), methanol (2 min ⁇ 1 ), and diethyl ether (2 min ⁇ 2). Every portion of the wash solution was 2 mL.
  • the synthetic cycle comprised: (1) 10-min activation of the Fmoc amino acid to be attached (3 equiv.) with DIC (3 equiv.) and HOBt (3.6 equiv.) in 1 mL DMF; (2) deblocking ⁇ -amino groups by exposure to a 20% solution of piperidine in DMF (3 mL ⁇ 3) for 30 min; (3) washing the peptidyl polymer with DMF (1.5 mL ⁇ 8 ⁇ 3 min); (4) additionally washing the peptidyl polymer with a solution of HOBt (3.6 equiv.) in 1.5 mL DMF for 3 min; (5) condensation of the activated Fmoc amino acid (3 equiv.) with the peptidyl polymer for 24 h; (6) washing the peptidyl polymer with DMF (1.5 mL ⁇ 2 ⁇ 2 min); and (7) monitoring the completion of substitution of amino groups upon the attachment of every next Fmoc amino acid by the ninhydrin test; if the test
  • the hemin peptidyl polymer was washed with DCM (2 mL ⁇ 2 ⁇ 2 min), vacuum dried with a water-jet pump, added with 4.5 mL of TFA-TFE-DCM (1:1:8), and then stirred under a nitrogen atmosphere for 3 h.
  • the polymer was separated and washed with TFA-TFE-DCM (1:1:8) (1 mL ⁇ 4 ⁇ 1 min).
  • the residue was triturated with cool anhydrous diethyl ether (taken in a 10-to 12-fold excess in volume); a precipitate was filtered off, washed twice with diethyl ether, and vacuum dried.
  • a 200- ⁇ L portion of the stock solution was concentrated under nitrogen flow; a 0.4-mL portion of a buffer solution containing 10 mM Tris, 10 mM MES, 100 mM KCl, and 100 mM CF was added; and the mixture was shaken for 2 min and then subjected to three freezing/thawing cycles being shaken after the end of each cycle.
  • the resulting mixture of multilamellar liposomes was extruded through a polycarbonate filter with a pore diameter of 0.1 ⁇ m using an Avanti (Avanti Polar Lipids, USA) mini-extruder.
  • the CF not included into liposomes was separated by gel chromatography on Sephadex G-50. The Sephadex was left overnight in water to swell.
  • a 20-mL column was packed with swollen Sephadex and then equilibrated with 60 mL of a buffer containing 10 mM Tris, 10 mM MES, and 100 mM KCl (buffer A).
  • the volume of the CF-containing liposome suspension was 500 ⁇ L (the lipid concentration was 0.045 mg/mL).
  • the suspension was placed into a cell, and the volume was adjusted to 2 mL with buffer A.
  • To the resulting liposome suspension added was 10 ⁇ L of a 10 -4 M solution of a hemin derivative of general formula (I) in DMSO.
  • the dynamics of CF release was monitored fluorimetrically.
  • Carboxyfluorescein fluorescence was excited at a wavelength of 490 nm and detected at 520 nm (the two slits were each 5 nm wide).
  • Figure 1 shows the dynamics of carboxyfluorescein release from liposomes under the effect of hemin derivatives of general Formula (I) for the lipid/hemin derivative ratio of 10:1 (mol/mol).
  • the antibacterial activity of compounds was determined against Bacillus subtilis BKM B-501, Staphylococcus aureus 209P, Enterococcus faecalis BKM B-871, and Micrococcus luteus BKM Ac-2230 strains (acquired from the All-Russia Collection of Microorganisms at the Institute for Biochemistry and Physiology of Microorganisms, Russian Academy of Sciences).
  • the main parameters characterizing the antibacterial activity are the minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC).
  • MIC is the least concentration of a tested compound that completely inhibits the reproduction of bacteria in a liquid medium.
  • MBC is the least concentration that causes the death of all cells.
  • MIC was quantified by inhibiting culture growth in a liquid medium with serial dilutions of compounds using a modified procedure [ Amsterdam, D., "Susceptibility Testing of Antimicrobials in Liquid Media,” in Antibiotics in Laboratory Medicine, Ed. by Loman, V, 4th ed., Baltimore: Williams and Wilkins, 1996, pp. 52-111 ].
  • Bacteria were cultured and tests were carried out on an MH liquid medium (Mueller-Hinton medium: a dry extract of beef broth, 4 g/L; starch, 1.5 g/L; casein hydrolyzate, 17.5 g/L; Sigma-Fluka Catalog No. 70192) at 37°C, 100% humidity, and under stirring. Cultures (4th through 7th receeding post-thawing) in the exponential growth phase were used for tests.
  • MH liquid medium Meeller-Hinton medium: a dry extract of beef broth, 4 g/L; starch, 1.5 g/L; casein hydrolyzate, 17.5 g/L; Sigma-Fluka Catalog No. 70192
  • the protocol for experimental antibacterial activity determination for tested compounds was as follows. A cryovial with the test strain culture ( Bacillus subtilis BKM B-501, Staphylococcus aureus 209P, Enterococcus faecalis BKM B-871, or Micrococcus luteus BKM Ac-2230) in a medium with 7% DMSO stored in liquid nitrogen, was rapidly defrosted, and 1.5 mL of the fresh MH medium was inoculated with 100 ⁇ L of the cell suspension. Cells were grown for one day at 37°C and stirred on an orbital shaker at 150 rpm.
  • test strain culture Bacillus subtilis BKM B-501, Staphylococcus aureus 209P, Enterococcus faecalis BKM B-871, or Micrococcus luteus BKM Ac-2230
  • the morphologic features of the strain and the absence of contamination with foreign bacteria were verified by: (a) inoculation on an agarized (15 g/L agar) MH medium and observation of the shape and color of the grown colonies and (b) examination of characteristic morphologic features under a microscope (Mikmed-2, LOMO, Russia) equipped with a 40x objective lens. Further bacteria were cultured in 1 mL of the liquid MH medium at 37°C under stirring. The cells were reseeded every day. Cell cultures were used in tests starting with 3rd reseeding and ending with 6th one.
  • a bacterial suspension in the stationary growth phase was transferred to 1 mL of a sterile MH medium and incubated until the exponential growth phase was attained (3 to 5 h, 37°C, stirring at 150 rpm).
  • the optical density (A) of the resulting bacterial culture was measured at a wavelength of 595 nm.
  • the value of A 0.2 measured from a 200- ⁇ L portion of the cell suspension in a 96-well plate, with a correction for the medium absorption applied, was set to correspond to 4 ⁇ 10 8 cells/mL for both strains used.
  • the suspension was diluted with the MH medium to a concentration of from 5 ⁇ 10 4 to 1 ⁇ 10 5 cells/mL and transferred to a sterile 96-well plate in an amount of 100 ⁇ L per well. Then, the cells were added with tested compounds and twofold serial dilutions of these compounds in plate's wells were made.
  • the maximal concentration of a compound in the series was 10 -4 M; the minimal one was 1.6 ⁇ 10 -6 M.
  • the antibacterial activity studies were performed in two replicas for each compound, and the results were averaged.
  • the controls used were: 100 ⁇ L of an additive-free bacterial culture (four wells); a bacterial culture added with 1% DMSO or water in the same volume as in the wells with the maximal concentration of the tested compounds (four wells); and 100 ⁇ L of the sterile MH medium without bacteria and without tested compounds for control of occasional contamination in the plate (four wells).
  • the medium from wells wherein the tested compound concentration equaled MIC, MIC ⁇ 2, or MIC ⁇ 4 was transferred to Petri dishes with an agarized MH medium (15 g/L agar) and uniformly spread over the area of the dish using sterile spatulas. The dishes were incubated for two days. MBC was determined as the least concentration of the tested compound at which colonies were not grown on Peti dishes.
  • M. luteus bacteria are highly sensitive to the compounds under consideration.
  • Compounds V, VI, VII, VIII, IX, hemin, GrD, and gramicidin S inhibit the growth of M. luteus in concentrations of up to 30 ⁇ M.
  • MICs are rather low (lower than 10 ⁇ M).
  • E. faecalis enterococci are (on the average) more resistant to the compounds under consideration than M. luteus micrococci or S . fureus staphylococci.
  • the tested agents were water-soluble hemin derivatives (compounds VII and XVIII) or DMSO-soluble derivatives (compounds VIII, XV, and XIV). Vancomycin was the reference compound. Each compound was tested in three replicas.
  • the nutritional media used were as follows. A working Mueller Hinton broth was prepared from dry media (Mueller Hinton broth, Acumedia, Baltimore) and sterilized by autoclaving at 121 °C for 15 min.
  • Staphylococcus aureus was cultured on the Tripticase Soy Agar (BBL) commercially available dry medium. Enterococcus faecalis was cultured on the Columbia Agar Base (BBL) commercially available dry medium. These media were sterilized by autoclaving at 121 °C for 15 min.
  • Bacterial inoculum was fixed and equal to 5 ⁇ 10 5 CFU/mL.
  • DMSO-soluble compounds For DMSO-soluble compounds, wells from 2nd through 8th were added with the solvent DMSO) in an amount of 10 ⁇ L per well, then the 1st well was added with 20 ⁇ L of the stock solution of the tested compound in water with a concentration of 5 ⁇ 10 3 M, and the concentration was adjusted to 0.039 ⁇ 10 3 M by serial twofold dilutions. A 2- ⁇ L portion was taken from each well, and 198 ⁇ L of the bacterial culture (10 5 CFU) was added per well.
  • the control comprised wells free of tested compounds (culture growth control). In addition, purity control of nutritional media and solvents was used. Plates were incubated in a thermostat at 36°C for 24 hours.
  • MSC the minimal suppressing concentration
  • hemin derivatives of general formula (I) are to various degrees active against resistant Gr+ bacterial strains.
  • the hemolysis efficacy was determined as the hemoglobin release from erythrocytes in the RPMI-1640 medium (without Phenol Red and with addition of 10% fetal bovine serum and 20 mM L-glutamine) for an initial erythrocyte density of (1.0 ⁇ 0.1) ⁇ 10 7 cells/mL after 3-h incubation with an agent (37°C, 5% CO 2 , 100% humidity, stirring on an orbital shaker).
  • the hemolytic activity was characterized by the hemoglobin fraction released from erythrocytes to the external medium. Erythrocytes, erythrocyte ghosts, and intermediate species containing unreleased hemoglobin were separated by centrifugation. Hemoglobin was quantified by the absorption of the supernatant at a wavelength of 414 nm (near the Soret band maximum for the heme).
  • the hemoglobin release fraction equals the lysed erythrocyte fraction provided that lysis is complete, that is, that
  • the experimental protocol for hemolytic activity determination was as follows. Blood (100 ⁇ L) was collected from a finger of a healthy donor into a test tube containing 0.9 mL of the RPMI-1640 medium (without Phenol Red) and heparin (10 units/mL). Cells were sedimented by centrifugation for 5 min at 200 ⁇ g and transferred to 10 mL of the RPMI-1640 medium (without Phenol Red with addition of 10% fetal calf serum and 20 mM L-glutamine; hereinafter, the complete medium). The erythrocyte density in the suspension was determined by counts in Goryachev's chamber using a Mikmed-2 (LOMO, Russia) microscope, and the suspension was diluted to (2 ⁇ 0.2) ⁇ 10 7 cells/mL with the complete medium.
  • LOMO LOMO, Russia
  • Negative controls were prepared as follows. To 75 ⁇ L of an erythrocyte suspension with a density of (2 ⁇ 0.2) ⁇ 10 7 cells/mL added was: (a) 75 ⁇ L of the complete medium (four samples), (b) 60 ⁇ L of the complete medium and 15 ⁇ L of water (four samples), or (c) 73.5 ⁇ L of the complete medium and 1.5 ⁇ L of DMSO (four samples).
  • erythrocytes from a 75- ⁇ L portion of the suspension were sedimented by centrifugation (5 min at 200 ⁇ g), the sediment was resuspended in deionized water (50 ⁇ L), and after lysis was complete the sample volume was adjusted to 150 ⁇ L with the complete medium.
  • Compound XII does not manifest hemolytic activity until its concentration is 100 ⁇ M.
  • Compounds V, VI, VIII, IX, and XVIII have low hemolytic activities ( Fig. 2 ); the hemolytic efficacy for all of the compounds synthesized is lower than for hemin, and is very low even for the maximal concentrations of the compounds (100 ⁇ M).
  • Total leukocytes were isolated from human blood by unforced sedimentation using freshly collected venous blood from a healthy donor.
  • the concentrations of leukocytes and erythrocytes in the suspension were determined by counts in Goryachev's chamber, after which the suspension was adjusted to a leukocyte concentration of (1.0 ⁇ 0.1) ⁇ 10 6 cells/mL with the complete medium.
  • the erythrocyte concentration in the blood cell suspension used for measurements did not exceed 30% of the leukocyte concentration.
  • the cell suspension was transferred to wells of sterile 96-well plates, tested compounds were added with serial twofold dilutions (the range of tested concentrations was from 3.2 to 100 ⁇ M for GrD and gramicidin S; from 8 to 500 ⁇ M for compound XIII; and from 8 to 1000 ⁇ M for compounds V, VI, VII, VIII, IX, X, XI, XIV, XV, XIX, and Hem), and the mixture was carefully stirred. The experiment was performed in two replicas.
  • Cells were incubated with tested compounds for 3 h (37°C, 5% CO 2 , 100% humidity). Leukocyte death values were quantified using fluorescence microscopy. Staining with propidium iodide (it permeates only into dead cells nuclei) and Hoechst 33342 (it stains all nuclei) was used to recognize dead and living cells. Cells were incubated for 15 min in plates with propidium iodide and Hoechst 33342 (37°C, 5% CO 2 ), and then the plates were placed under a microscope for analysis.
  • the dead cell fraction was derived from the fluorescence images of cells obtained in the blue (Hoechst 33342) and red (propidium iodide) spectral ranges using an Axio Observer (Zeiss, Germany) fluorescence microscope equipped with a 10x objective lens (Plan-Neofluar 10 ⁇ /0.3).
  • the following sets of fluorescence filters were used.
  • propidium iodide a 530/585-nm bandpass excitation filter, a 600-nm cut-off dichroic mirror, and a 615-nm longpass barrier filter for analysis.
  • Hoechst 33342 a 359/372-nm bandpass excitation filter, a 395-nm cut-off dichroic mirror, and a 397-nm longpass barrier filter for analysis.
  • a digital camera recorded three types of cell images: (a) an image in the transmitted white light; (b) a blue fluorescence image obtained with UV excitation, and (c) a red fluorescence image obtained with green light excitation. At least four fields of view were photographed per well in various regions of a well. The results of analysis were averaged over 1000 to 1500 cells for every concentration of a tested compound.
  • the subjects of action were Cryptococcus neoformans No. 3465 museum strain cells and Candida albicans No. 927 museum strain cells grown for one day on a glucose-peptone-yeast medium at 32°C.
  • the reference compounds were the following antimycotics: pimafucin, amphotericin, and fluconazole.
  • the synthetic medium comprised the following components: salts, amino acids, microelements, vitamins, an antibiotic, and glucose (30 components altogether) [ Yarrow, D., "Methods for the Isolation, Maintenance and Identification of Yeasts," in: The Yeasts. A Taxonomic Study, Ed.
  • compound XII appeared efficacious against one cryptococcosis causative agent (Cryptococcus humicolus) with an MSC of 12.5 ⁇ M.
  • compounds of general formula (I) exert a fungistatic and/or fungicidal effects, where the size of the effect is structure dependent and manifests itself in the range of concentrations from 10 -4 to 10 -6 M.
  • the powder to be introduced into capsules is formulated as follows: A compound corresponding to the general formula (I) 1 to 50 mg Magnesium oxide 50 mg Starch 100 to 200 mg
  • the above-listed ingredients are blended, and the blend is introduced into hard gelatin capsules in an amount of from 151 to 285 mg.
  • a tablet dosage form is manufactured using the ingredients listed below: A compound corresponding to the general formula (I) 1 to 50 mg Potato starch 100 mg Polyvinylpyrrolidone 10 mg Magnesium stearate 2 mg Lactose 48 to 82 mg Aerosil 5 mg
  • the components are blended and compacted to produce tables each weighing 200 mg.
  • An aerosol blend intended for 10-time administration is formulated as follows: A compound corresponding to the general formula (I) 10 to 100 mg Magnesium sulfate 150 mg Lactose 110 to 140 mg
  • the compound is blended with excipients, and the blend is transferred into a special spraying device.
  • An example ointment formulation A compound corresponding to general formula (I) 0.01 g to 0.1 g Vaseline 10 g
  • Ointments are prepared by the proper technologies.
  • the solvents useful to prepare solutions for injection include 0.9% sodium chloride solution, distilled water, and Novocain solution.
  • Unit dosage forms may be manufactured as ampoules, vials, and ampins.
  • the formulation of the solution for injection is as follows: A compound corresponding to the general formula (I) 1-50 mg Distilled water 1 to 2 mL
  • Injection dosage forms may be manufactured as sterile solutions, sterile powders, and sterile tablets.
  • a compound corresponding to the general formula (I) 0.001 to 1% Dimethyl sulfoxide (DMSO) 1 to 20% or polyethylene glycol (PEG) with MM 200 to 12 000 1 to 20% Distilled water Up to 100% D.
  • DMSO Dimethyl sulfoxide
  • PEG polyethylene glycol
  • a compound corresponding to the general formula (1) 0.001 to 1%
  • Compounds corresponding to the general formula (I) 0.001 to 1% Distilled water Up to 100%
  • hemin derivatives of general formula (I) have antibacterial and antifungal activities, in particular against human-pathogenic S. aureus and its resistant strains. Further, almost all of the claimed hemin derivatives are capable (in various degrees) of increasing the permeability of model lipid membranes, which is known from the literature to be an important part of the mechanism of the antimicrobial (antibacterial, antifungal) effect of antimicrobial agents.
  • the efficacy of the compounds of general formula (I) proves their suitability for large-scale use in formulations of disinfectant, antiseptic, and therapeutic agents having an antifungal and antibacterial effect.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP10815682.9A 2009-09-10 2010-09-08 Antimikrobielle mittel auf basis von hemin-derivaten Active EP2476701B8 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL10815682T PL2476701T3 (pl) 2009-09-10 2010-09-08 Środki przeciwdrobnoustrojowe na bazie pochodnych heminy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2009133914/04A RU2415868C1 (ru) 2009-09-10 2009-09-10 Производные гемина, обладающие антимикробной активностью, или их фармацевтически приемлемые соли, способ получения, фармкомпозиция и применение
PCT/RU2010/000488 WO2011031187A1 (ru) 2009-09-10 2010-09-08 Антимикробные средства на основе производных гемина

Publications (4)

Publication Number Publication Date
EP2476701A1 true EP2476701A1 (de) 2012-07-18
EP2476701A4 EP2476701A4 (de) 2013-01-16
EP2476701B1 EP2476701B1 (de) 2014-08-13
EP2476701B8 EP2476701B8 (de) 2014-09-24

Family

ID=43732659

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10815682.9A Active EP2476701B8 (de) 2009-09-10 2010-09-08 Antimikrobielle mittel auf basis von hemin-derivaten

Country Status (11)

Country Link
US (1) US8906897B2 (de)
EP (1) EP2476701B8 (de)
CN (1) CN102906110B (de)
DK (1) DK2476701T3 (de)
EA (1) EA020802B1 (de)
ES (1) ES2527432T3 (de)
IN (1) IN2012DN02980A (de)
PL (1) PL2476701T3 (de)
RU (1) RU2415868C1 (de)
UA (1) UA108480C2 (de)
WO (1) WO2011031187A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781525A4 (de) * 2011-11-17 2015-05-27 Obschestvo S Ogranichennoi Otvetstennostiyu Pharmentpr Neue derivate von hemin mit antibakterieller und antiviraler wirkung

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102967649B (zh) * 2012-05-24 2015-03-04 新疆科丽生物技术有限公司 电感耦合等离子体质谱在氯高铁血红素药物检测中的应用
EP3295962B1 (de) * 2016-09-15 2021-01-27 Nano4Imaging GmbH Tetrapyrrolkonjugate als mrt-kontrastmittel
RU2678985C2 (ru) 2017-02-06 2019-02-05 Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" Биоцидный пептид и препарат на его основе
WO2019023706A1 (en) * 2017-07-28 2019-01-31 The Penn State Research Foundation ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR ADMINISTRATION OF SPACE-RESOLVED MOLECULES
RU2656595C1 (ru) * 2018-03-16 2018-06-06 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Циклическое производное гемина с антимикробными свойствами и способ его синтеза

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629198A (en) * 1991-08-02 1997-05-13 Meiji Milk Products Co., Ltd. Anti-HIV agent
IL116126A0 (en) 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
US6001808A (en) 1996-08-19 1999-12-14 Metatron, Inc. Method of treating herpes virus infections with spermostatic gramicidin
RU2238950C2 (ru) * 2002-04-25 2004-10-27 Небольсин Владимир Евгеньевич Производные гемина и их фармацевтически приемлемые соли, способ получения, применение и фармацевтическая композиция
RU2250906C2 (ru) * 2003-07-10 2005-04-27 Небольсин Владимир Евгеньевич Способы получения геминпептидов и их применение в качестве нуклеолитических агентов
RU2296131C2 (ru) * 2004-11-26 2007-03-27 ООО "Фарминтерпрайсез" Геминпептид, его фармацевтически приемлемые соли и применение в качестве противовирусного и вирулецидного агента
RU2280649C1 (ru) 2004-11-26 2006-07-27 ООО "Фарминтерпрайсез" Геминпептиды, их фармацевтически приемлемые соли, фармкомпозиция и применение в качестве противоопухолевых агентов
RU2404191C2 (ru) * 2007-07-09 2010-11-20 ООО "Фарминтерпрайсез" Производные гемина или их фармацевтически приемлемые соли, способ получения, композиция и применение

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IGOR STOJILJKOVIC ET AL: "Antimicrobial properties of porphyrins", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 10, no. 2, 1 February 2001 (2001-02-01), pages 309-320, XP008135744, ISSN: 1354-3784 *
See also references of WO2011031187A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781525A4 (de) * 2011-11-17 2015-05-27 Obschestvo S Ogranichennoi Otvetstennostiyu Pharmentpr Neue derivate von hemin mit antibakterieller und antiviraler wirkung

Also Published As

Publication number Publication date
RU2415868C1 (ru) 2011-04-10
UA108480C2 (en) 2015-05-12
PL2476701T3 (pl) 2015-03-31
EP2476701B1 (de) 2014-08-13
HK1179278A1 (zh) 2013-09-27
CN102906110B (zh) 2016-04-13
EP2476701A4 (de) 2013-01-16
CN102906110A (zh) 2013-01-30
US20120264724A1 (en) 2012-10-18
IN2012DN02980A (de) 2015-07-31
EA020802B1 (ru) 2015-01-30
EP2476701B8 (de) 2014-09-24
EA201270405A1 (ru) 2012-08-30
DK2476701T3 (en) 2014-11-17
ES2527432T3 (es) 2015-01-23
WO2011031187A1 (ru) 2011-03-17
US8906897B2 (en) 2014-12-09

Similar Documents

Publication Publication Date Title
Zhong et al. Design and synthesis of new N-terminal fatty acid modified-antimicrobial peptide analogues with potent in vitro biological activity
EP2476701B1 (de) Antimikrobielle mittel auf basis von hemin-derivaten
KR101345333B1 (ko) 라이신 및 트립토판 잔기가 ４번 반복된 신규한 항균 및 항진균 펩타이드 및 이의 용도
KR100879211B1 (ko) 개불 유래의 새로운 항균 펩타이드 및 그의 용도
US9605013B2 (en) Derivatives of hemin with antibacterial and antiviral activity
US20060128614A1 (en) Antimicrobial peptides with reduced hemolysis and methods of their use
CN111819187A (zh) 多肽化合物及其制备方法与应用
CN115028685B (zh) 一种阳离子双环抗菌肽及其应用
US9090655B2 (en) Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof
US6800727B2 (en) Peptides with increased + charge and hydrophobicity by substituting one or more amino acids of CA-MA peptide and pharmaceutical compositions containing thereof
JP2013523661A (ja) 低赤血球溶解性の抗微生物ペプチド、医薬組成物およびその使用
CN112457375B (zh) 多肽化合物及其制备方法与应用
KR100911375B1 (ko) 개불 유래의 새로운 유사체 항균 펩타이드 및 그의 용도
HK1179278B (en) Antimicrobial agents based on hemin derivatives
US20200216497A1 (en) NOVEL ANTIMICROBIAL PEPTIDE DERIVED FROM Hp1404 PEPTIDE AND USES THEREOF
KR100935029B1 (ko) 헬리코박터 파일로리균의 리보좀 단백질 ｌ１유래의 새로운접힘 구조를 갖는 항생 펩타이드 및 조성물
US7449545B2 (en) Antimicrobial bolisin peptides
WO2020065595A1 (es) Lipopeptidos cortos con actividad antimicrobiana contra bacterias gram negativas y gram positivas
CN102329375A (zh) 一组末端酰胺化的抗菌肽

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

A4 Supplementary search report drawn up and despatched

Effective date: 20121218

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/805 20060101AFI20121212BHEP

Ipc: C07F 15/02 20060101ALI20121212BHEP

Ipc: A61P 31/04 20060101ALI20121212BHEP

Ipc: C07D 487/22 20060101ALI20121212BHEP

Ipc: A61K 38/42 20060101ALI20121212BHEP

Ipc: A61P 31/10 20060101ALI20121212BHEP

17Q First examination report despatched

Effective date: 20130905

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140306

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 682207

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140815

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHAR

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010018307

Country of ref document: DE

Effective date: 20141002

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20141113

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2527432

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150123

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141113

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141114

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141215

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141213

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010018307

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: BE

Effective date: 20150206

26N No opposition filed

Effective date: 20150515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140908

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140908

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100908

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20190924

Year of fee payment: 10

Ref country code: NL

Payment date: 20190926

Year of fee payment: 10

Ref country code: FR

Payment date: 20190926

Year of fee payment: 10

Ref country code: TR

Payment date: 20190826

Year of fee payment: 10

Ref country code: RO

Payment date: 20190829

Year of fee payment: 10

Ref country code: IT

Payment date: 20190923

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20190819

Year of fee payment: 10

Ref country code: BE

Payment date: 20190926

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20190926

Year of fee payment: 10

Ref country code: GB

Payment date: 20190930

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20190925

Year of fee payment: 10

Ref country code: DE

Payment date: 20191129

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20191021

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602010018307

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20200930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200908

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20201001

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 682207

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200908

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200908

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210401

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200908

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200930

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200908

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200930

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200930

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200909

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200908